Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?

IF 13.3 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2026-08-14 DOI:10.1016/j.medj.2026.101227

Giulia Orsi, Michele Reni

引用次数: 0

Abstract

The phase 3 RASolute 302 trial demonstrated significant overall and progression-free survival benefits with daraxonrasib over investigator's choice chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma harboring RAS G12 mutations after progression on prior chemotherapy.¹ The benefit in patients with non-G12 RAS mutations or RAS wild-type tumors remains unclear.

查看原文本刊更多论文

难治性PDAC中的Daraxonrasib：盲人之地的独眼国王？

3期RASolute 302试验显示，在先前化疗进展后携带RAS G12突变的转移性胰腺导管腺癌患者中，与研究者选择的化疗相比，daraxonrasib显着的总体和无进展生存期获益非g12 RAS突变或RAS野生型肿瘤患者的获益尚不清楚。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.